SpectrumDNA Stock

SpectrumDNA Equity

The The Equity of SpectrumDNA (SPXA) as of Jul 17, 2026 is 383,400.00 USD.

Equity

383,400.00USD

Last updated:

In 2026, SpectrumDNA's equity was 383,400.00 USD, a % increase from the - USD equity in the previous year.

Access this data via the Eulerpool API

SpectrumDNA Stock analysis

What does SpectrumDNA do? SpectrumDNA Inc is a company specializing in the development and marketing of genetic tests and analyses. Founded in 2013, the company is based in Austin, Texas and is one of the leading companies in the field of DNA analysis. The history of SpectrumDNA goes back to its founders, Dr. Jamie Teumer and Dr. João Silveira. Both bring years of experience in genetics and molecular biology and have worked on numerous research projects. Their goal was to make genetics accessible to everyone and improve healthcare. With this drive, they founded SpectrumDNA and began to put their idea into action. SpectrumDNA's business model is based on the creation of genetic tests and analyses that allow people to know their personal risk for certain diseases or conditions and take targeted preventive measures. SpectrumDNA works closely with doctors and other healthcare experts to interpret and implement the results and recommendations of the tests. SpectrumDNA offers a variety of genetic tests and analyses targeting various areas of health and well-being. These include tests for identifying genetic risk factors for cancer, cardiovascular diseases, Alzheimer's, and Parkinson's, as well as tests for predicting behavioral traits and physical characteristics such as lactose intolerance or hair color. The company also has its own research and development department that constantly works on advancing and improving test methods and technologies. This ensures that customers at SpectrumDNA always receive the latest and most accurate information. SpectrumDNA has also specialized in developing products based on the genetic profiles of its customers. These include personalized supplements tailored to the individual needs of the customer, as well as personalized training plans based on the customer's genetic traits. Recently, SpectrumDNA has also focused its attention on the application of genetics in the beauty industry. The company has developed a procedure that allows the analysis of skin quality and aging process based on the customer's genetic profile. Based on this analysis, a personalized skincare program is created that is tailored to the individual needs and goals of the customer. Overall, SpectrumDNA is a leading company in the field of DNA analysis and specializes in personalized healthcare services. Through close collaboration with doctors and other healthcare providers, as well as constant advancement and improvement of its technologies and products, SpectrumDNA enables its customers to improve their health and well-being in a personalized and effective way. SpectrumDNA is one of the most popular companies on Eulerpool.

Equity Details

Analyzing SpectrumDNA's Equity

SpectrumDNA's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding SpectrumDNA's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating SpectrumDNA's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

SpectrumDNA's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in SpectrumDNA’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about SpectrumDNA stock

The Equity of SpectrumDNA is 383,400.00 USD in 2026.

Access this data via the Eulerpool API

Balance Sheet — SpectrumDNA

All Key Metrics — SpectrumDNA